Spanish Site Doubles Production Capacity for Temperature Control Technology
Temperature control specialist Lauda Dr R. Wobser GmbH & Co KG, Lauda Ultracool, SL, has offi cially inaugurated its new production site in Terrassa, near Barcelona, marking the completion of the fi rst construction project abroad for the company. The family company has invested around seven million euros in the new-build, creating around 4,000 m² of new production areas and almost 1,000 m² of offi ce space on the 9,000 m² site. The resulting doubling of production capacities for Lauda Ultracool circulation chillers, is set to meet growing demand worldwide for energy-effi cient industrial cooling, said the company. The expansion of the Spanish subsidiary is strategically aligned with Lauda’s ambitious Drive250 strategy project, which aims to more than double company revenue within fi ve years.
Along with the workforce and Managing Director of Lauda Ultracool, Xavier Armengol, the festivities were attended by high-ranking representatives from Germany, including President & CEO Dr Gunther Wobser and his father Gerhard Wobser, as well as Managing Directors Dr Marc Stricker and Dr Mario Englert. Regional representatives included the Mayor of Terrassa Jordi Ballart and Deputy Mayor Núria Marin, and Patrick Heinz, the Deputy Consul General of the German Consulate General in Barcelona. Speeches by Ramon Talàmas, President of the Terrassa Chamber of Commerce, Joan Romero, Representative of the Catalonian Government and CEO of ACCIO, an
organisation to ensure the competitiveness of Catalonian businesses and Antoni Abad, President of the CECOT Entrepreneurs’ Association, praised the contribution and commitment of Lauda to the burgeoning economic region of Catalonia.
“In recent years, Lauda Ultracool has grown steadily and
successfully positioned itself on the market with modern, energy- effi cient circulation chillers,” said Dr Marc Stricker, summarising the developments of the last few years. “The new build will create urgently needed capacities for our biggest overseas subsidiary, both in production and for the further expansion of the product line. Accordingly, this important investment is perfectly in line with our Drive250 growth strategy.”
“Like in 2011, when we acquired the Spanish subsidiary, we are showing courage and investing during diffi cult times,” remarked Dr Gunther Wobser during his festive speech. “That’s why it is all the more important that we as a company send a visible signal of confi dence and determination. By doing so, we can write our success story together.”
More information online:
ilmt.co/PL/VE0d 59202pr@reply-direct.com
Pictured left to right: Ramon Talamàs, President of the Terrassa Chamber of Commerce, Joan Romero, Representative of the Catalonian Government and CEO of ACCIO, Xavier Armengol, Managing Director of Lauda Ultracool, Dr Gunther Wobser, President & CEO of Lauda, Jordi Ballart, Mayor of Terrassa, and Antoni Abad, President of the CECOT Entrepreneurs’ Association
Hiden Analytical Achieves ISO 14001:2015 Environmental Accreditation
Partnership to Identify Target Peptides
The agreement, covering activities ranging from hit ID to cell-based internalisation studies, has an option for Sanegene to further develop hits resulting from screening activities with a view to product development.
Dr Neil Butt, Chief Executive Offi cer of Orbit Discovery, commented: “Sanegene has established an incredible ability to screen for RNAi molecules in a robust and effi cient manner. We are delighted to leverage the speed and performance of the Orbit platform to enable Sanegene to generate specifi c targeting peptides.
“Our aim is to make screening more relevant to the fi nal biological read-outs, to ensure the right leads are selected fi rst time, every time. This has the end goal of enabling the generation of future therapeutics with low toxicity and tissue specifi city and ultimately safer and more effective medicines.”
Neil Butt
Hiden Analytical has achieved ISO 14001:2015 environmental accreditation.
Hiden Analytical is proud to announce that it has achieved the highly sought-after ISO 14001:2015 environmental accreditation, demonstrating the company’s commitment to
environmental
management in all aspects of its business. Hiden’s green strategies have
been essential to the implementation of an effective
environmental management system (EMS) which promotes resource effi ciency, cost reduction, and waste reduction.
Hiden has earned an impressive worldwide reputation due to its customer-driven
innovation, unique company culture, and
talented staff of over 120 scientists, engineers, technicians, and operations specialists. The company’s recent expansions include new cleanroom facilities for precision assembly, a new vacuum/ mechanical assembly suite, and additional offi ce space.
Hiden’s product range covers fi ve core application areas, including RGA, gas analysis, catalysis and thermal analysis, plasma characterisation, and surface analysis. The company also offers a bespoke design service that provides clients with customised solutions to meet their specifi c requirements.
More information online:
ilmt.co/PL/KVJX 59609pr@reply-direct.com
Start-up SanegeneBio Inc, focused on developing novel RNAi-based medicines has entered into a Master Service Agreement with Orbit Discovery (Oxford UK), a leader in the discovery of therapeutic peptide hits. The collaboration is focused on identifying tissue- specifi c delivery of a wide range of RNA therapeutics with potential to knock down disease-causing genes.
Dr Weimin Wang, Chief Executive Offi cer of SanegeneBio, said: “We selected Orbit as our discovery partner because of the team’s experience in overcoming peptide screening challenges alongside an industry-leading platform. We are confi dent that the combination of Orbit’s peptide discovery capabilities and our expertise in RNAi drug discovery and development will facilitate the accelerated entry of our therapeutics portfolio into the clinic.”
More information online:
ilmt.co/PL/d1Pj 59520pr@reply-direct.com
Milestone Reached in Target Discovery Alliance
Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop fi rst- in-class therapies to transform patients’ lives.
“The success of this project to date provides signifi cant validation of our SITESEEKER platform and its capabilities in novel target discovery and is testament to the expertise and great collaborative efforts of the teams at both PhoreMost and Boehringer Ingelheim. We are proud to contribute to the development of much needed new therapies for patients by delivering on this fi rst key milestone and look forward to continuing this very fruitful partnership” said Dr Neil Torbett, Chief Executive Offi cer, PhoreMost.
The development of potential new therapies will now be continued at Boehringer Ingelheim leading to possible further success based pre- clinical, clinical and commercial milestone payments.
Further information:
ilmt.co/PL/y1gk Neil Torbett
59521pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
